

Institut für kardiovaskuläre Pharmatherapie und interventionelle Kardiologie

Institutsleitung: Prim. Univ.-Prof. Priv.-Doz. Dr. Thomas Gremmel, MBA, FESC

Wissenschaftliche Publikationen 2022:

- 1) Impact of body size on platelet function in patients with acute coronary syndrome on dual antiplatelet therapy. Panzer B, Wadowski PP, Huber K, Panzer S, Gremmel T. *Vascul Pharmacol.* 2022 Oct;146:107089. doi: 10.1016/j.vph.2022.107089.
- 2) Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y12 inhibitors. Panzer B, Wadowski PP, Huber K, Panzer S, Gremmel T. *Diabet Med.* 2022 Aug;39(8):e14868. doi: 10.1111/dme.14868.
- 3) Growth Differentiation Factor-15 Correlates Inversely with Protease-Activated Receptor-1-Mediated Platelet Reactivity in Patients with Left Ventricular Assist Devices. Tscharrre M, Wittmann F, Kitzmantl D, Lee S, Eichelberger B, Wadowski PP, Laufer G, Wiedemann D, Panzer S, Perkmann T, Zimpfer D, Gremmel T. *Pharmaceuticals (Basel).* 2022 Apr 15;15(4):484. doi: 10.3390/ph15040484.
- 4) Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis. Brusilovskaya K, Simbrunner B, Lee S, Eichelberger B, Bauer D, Zinober K, Schwabl P, Mandorfer M, Panzer S, Reiberger T, Gremmel T. *Platelets.* 2022 Aug 18;33(6):879-886. doi: 10.1080/09537104.2021.2007868.
- 5) Platelet-to-Lymphocyte Ratio as Marker of Platelet Activation in Patients on Potent P2Y12 Inhibitors. Wadowski PP, Pultar J, Weikert C, Eichelberger B, Tscharrre M, Koppensteiner R, Panzer S, Gremmel T. *J Cardiovasc Pharmacol Ther.* 2022 Jan-Dec;27:10742484221096524. doi: 10.1177/10742484221096524.